Bennabi, D.
Charpeaud, T.
Yrondi, A.
Genty, J.-B.
Destouches, S.
Lancrenon, S.
Alaïli, N.
Bellivier, F.
Bougerol, T.
Camus, V.
Dorey, J.-M.
Doumy, O.
Haesebaert, F.
Holtzmann, J.
Lançon, C.
Lefebvre, M.
Moliere, F.
Nieto, I.
Rabu, C.
Richieri, R.
Schmitt, L.
Stephan, F.
Vaiva, G.
Walter, M.
Leboyer, M.
El-Hage, W.
Llorca, P.-M.
Courtet, P.
Aouizerate, B.
Haffen, E.
Article History
Received: 8 August 2018
Accepted: 12 August 2019
First Online: 28 August 2019
Ethics approval and consent to participate
: Not Required. Loi Jardé (decret 2016–1537).We have not included data from patients, only the opinion of medical experts who were agree to participate. These healthcare professionals, affiliated to the AFPBN, have received information about aims of the study, methods used and data collection in an information letter and have given their oral agreement to formalize the professional practices in France. Loi Jardé (decret 2016–1537).
: Not Applicable.
: No financial support was received for this study and there are no potential conflicts of interest to declare. Regarding financial support unrelated to the present article, we disclose that N. Alaïli has benefited from financial support for conferences and has been scientific responsible and experimenter for preclinical studies from Servier laboratories.B. Aouizerate has perceived honoraria to communicate at conferences from Laboratories AstraZeneca, Lundbeck and Janssen. V. Camus has benefited from honoraria and financial support for conferences from Laboratories Otsuka, Novartis, Lundbeck, Servier, Janssen and has been experimenter for studies from Janssen and Lilly.T. Charpeaud has benefited from honoraria and financial support for conferences from Laboratories AstraZeneca, Janssen and Lundbeck and has been experimenter for studies from Janssen. P. Courtet has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from Servier and Janssen. O. Doumy has benefited from honoraria and financial support for conferences from Lilly, AstraZeneca, Servier, Lundbeck and Janssen. JM. Dorey has benefited from honoraria for conferences from Lundbeck. W. El-Hage has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from Lundbeck, Janssen, and Otsuka.F. Haesebaert has benefited from financial support for conferences, grant from BMS and AstraZeneca, training grant from Servier and a research grant from « Fonds de Recherche du Québec - Nature et Technologie (#200123) » and has been experimenter for studies from Janssen. E. Haffen has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from AstraZeneca, BMS, Euthérapie u e Servier, Janssen, Livanova, Lundbeck, Otsuka and has been experimenter for studies from Janssen. J. Holtzmann has benefited from honoraria and financial support for conferences from Lundbeck, Servier has been experimenter for studies from Janssen. C. Lançon has benefited from honoraria and financial support for training action from Lundbeck. P.-M. Llorca has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from Janssen, EISAI, Lundbeck, Otsuka, Allergan.F. Moliere has benefited from honoraria for conferences from Lundbeck, Otsuka. G. Vaiva has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from Janssen and Otsuka. A. Yrondi has benefited from honoraria and financial support for conferences from Lundbeck, Janssen, AstraZeneca; for participation in experts groups from Lundbeck and has participated in reseach studies from Lundbeck.